The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue 1, 2009, Pages

  Stocchi, Fabrizio ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Continuous dopaminergic stimulation; Dyskinesias; Levodopa; Motor complications; Parkinson's disease

Indexed keywords

ANIMALS; DOPAMINE AGENTS; HUMANS; LEVODOPA; MOVEMENT DISORDERS; PARKINSON DISEASE; TIME FACTORS;

EID: 58149133708     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70005-7     Document Type: Article

References (90)

1. Olanow C.W., Watts R.L., and Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 56 Suppl 5 (2001) S1-86
2. Agid Y., Olanow C., and Mizuno Y. Levodopa: why the controversy?. Lancet 360 (2002) 575
3. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., and Lang A.E. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 (2002) 11-17
4. Rascol O., Goetz C., Koller W., Poewe W., and Sampaio C. Treatment interventions for Parkinson's disease: an evidence-based assessment. Lancet 359 (2002) 1589-1598
5. Korczyn A.D., and Nussbaum M. Emerging therapies in the pharmacological treatment of Parkinson's disease. Drugs 62 (2002) 775-786
6. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
7. Marsden C.D. Parkinson's disease. J Neurol Neurosurg Psychiatry 57 (1994) 672-681
8. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 7 (1992) 117-124
9. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., and Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 9 (1994) 2-12
10. Melamed E., Bitton V., and Zelig O. Episodic unresponsiveness to single doses of l-Dopa in parkinsonian fluctuators. Neurology 36 (1986) 100-103
11. Stacy M., Bowron A., Guttman M., Hauser R., Hughes K., Larsen J.P., et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 (2005) 726-733
12. Olanow C.W., Obeso J.A., and Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5 (2006) 677-687
13. Fabbrini G., Juncos J., Mouradian M.M., Serrati C., and Chase T.N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 21 (1987) 370-376
14. Fabbrini G., Mouradian M.M., Juncos J., Schlegel J., Mohr E., and Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 24 (1988) 366-371
15. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., and Chase T.N. Wearing-off fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 24 (1988) 372-378
16. Bravi D., Mouradian M.M., Roberts J.W., Davis T.L., Sohn Y.H., and Chase T.N. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36 (1994) 27-31
17. Muenter M.D., and Tyce G.M. l-dopa therapy of Parkinson's discese in plasma l-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46 (1971) 231-239
18. Kaye J.A., and Feldman R.G. The role of l-dopa holiday in the long term management of Parkinson's disease. Clin Neuropharmacol 9 (1986) 1-13
19. Barbato L., Stocchi F., Monge A., Vacca L., Ruggieri S., Nordera G., et al. The long-duration action of levodopa may be due to a post-synaptic effect. Clin Neuropharmacol 20 (1997) 394-401
20. Zappia M., Oliveri R.L., Bosco D., Nicoletti G., Branca D., Caracciolo M., et al. The long-duration response to l-dopa in the treatment of early PD. Neurology 54 (2000) 1910-1915
21. Zappia M., Oliveri R.L., Montesanti R., Rizzo M., Bosco D., Plastino M., et al. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 52 (1999) 763-767
22. Zappia M., Bosco D., Plastino M., Nicoletti G., Branca D., Oliveri R.L., et al. Pharmacodynamics of the long-duration response to levodopa in PD. Neurology 53 (1999) 557-560
23. Stocchi F., Vacca L., Berardelli A., De Pandis M.F., and Ruggieri S. The long-lasting effect and the postsynaptic compartment: a study using a dopamine agonist with a short half-life. Mov Disord 16 (2001) 301-305
24. Nutt J.G., Woodward W.R., Carter J.H., and Gancher S.T. Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon. Arch Neurol 49 (1992) 1123-1130
25. Rodriguez M., Lera G., Vaamonde J., Luquin M.R., and Obeso J.A. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 57 (1994) 562-566
26. Baruzzi A., Contin M., Riva R., Procaccianti G., Albani F., Tonello C., et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 10 (1987) 527-537
27. Edwards L.L., Quingley E., and Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 42 (1992) 726-732
28. Valenzuela J.E. Dopamine as a possible neurotransmitter in gastric relaxation. Gastroenterology 71 (1976) 1019-1022
29. Leon A.S., and Speigel H. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol 12 (1972) 263-267
30. Sage J.I., Trooskin S., Sonsalla P.K., Heikkila R.E., and Duvoisin R.C. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 24 (1998) 87-89
31. Kurlan R., Rubin A.J., Miller C., Rivera-Calimlim L., Clarke A., and Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: Preliminary observations. Ann Neurol 20 (1986) 262-265
32. Syed N., Murphy J., Zimmerman T., Mark M.H., and Sage J.I. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 13 (1998) 336-338
33. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., and Anderson J.L. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 310 (1984) 483-488
34. 19F)-fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20 (1986) 258-262
35. Kelly K.A. Motility of the stomach and gastroduodenal junction. In: Johnson L.R. (Ed). Physiology of the gastrointestinal tract (1981), Raven Press, New York 394-410
36. Stocchi F., Ruggieri S., Monge A., Nordera G., Bolner P., Viselli F., et al. Clinical efficacy of single morning doses of different levodopa formulations. Clin Neuropharmacol 17 Suppl 3 (1994) S16-S20
37. Stocchi F., Barbato L., Bramante L., Nordera G., Vacca L., and Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol 243 (1996) 377-380
38. Stocchi F., Fabbri L., Vecsei L., Krygowska-Wajs A., Monici Preti P.A., and Ruggieri S. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 30 (2007) 18-24
39. Stocchi F. Optimising levodopa therapy for the management of Parkinson's disease. J Neurol 252 supp 4 (2005) 43-48
40. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991) 1-24
41. Schultz W. Predictive reward signal of dopamine neurons. J Neuro-physiol 80 (1998) 1-27
42. Abercrombie E.D., Bonatz A.E., and Zigmond M.J. Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525 (1990) 36-44
43. Venton B.J., Zhang H., Garris P.A., Phillips P.E., Sulzer D., and Wightman R.M. Real-time decoding of dopamine concentrating changes in the caudate-putamen during tonic and phasic firing. J Neurochem 89 (2004) 1284-1295
44. Calabresi P. Electrophysiology of dopamine-denervated striatal neurons; implications for Parkinson's disease. Brain 116 (1993) 433-452
45. Centonze D., Gubellini P., Picconi B., Calabresi P., Giacomini P., and Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol 82 (1999) 3575-3579
46. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 6 (2003) 501-506
47. Rodriguez M., Gonzalez J., Sabate M., Obeso J., and Pereda E. Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons. Eur J Neurosci 18 (2003) 53-60
48. Stephens B., Mueller A.J., Shering A.F., Hood S.H., Taggart P., Arbuthnott G.W., et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 132 (2005) 741-754
49. Zaja-Milatovic S., Milatovic D., Schantz A.M., Zhang J., Montine K.S., Samii A., et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64 (2005) 545-547
50. Tremblay L., Filion M., and Bedard P.J. Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism. Brain Res 498 (1989) 17-33
51. Filion M., Tremblay L., and Bedard P.J. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 444 (1988) 165-176
52. Abercrombie E.D., Bonatz A.E., and Zigmond M.J. Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525 (1990) 36-44
53. De la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., et al. Levodopa-induced changes in synaptic dopaminelevels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 127 (2004) 2747-2754
54. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
55. 3H]spiperone binding. Brain Res 379 (1986) 294-299
56. Pearce R.K., Banerji T., Jenner P., and Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset. Mov Disord 13 (1998) 234-241
57. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 47 (2000) S90-S99
58. Blanchet P.J., Calon F., Martel J.C., Bédard P.J., Di Paolo T., Walters R.R., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272 (1995) 854-859
59. Bibbiani F., Costantini L.C., Patel R., and Chase T.N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 192 (2005) 73-78
60. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bédard P.J., et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with l-DOPA therapy. Brain Res Mol Brain Res 49 (1997) 55-62
61. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
62. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di Paolo T., et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47 (2000) 70-78
63. Cenci M.A., Tranberg A., Andersson M., and Hilbertson A. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment. Neuroscience 94 (1999) 515-527
64. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., and Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61 (2002) 186-196
65. Boraud T., Bezard E., Bioulac B., and Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 124 (2001) 546-557
66. Brown P., Oliviero A., Mazzone P., Insola A., Tonali P., and Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21 (2001) 1033-1038
67. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., et al. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25 (1989) 473-478
68. Engber T.M., Susel Z., Juncos J.L., and Chase T.N. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 168 (1989) 291-298
69. Engber T.M., Susel Z., Kuo S., Gerfen C.R., and Chase T.N. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 552 (1991) 113-118
70. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 (2000) 1484-1491
71. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284 (2000) 231-238
72. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54 (2003) 93-101
73. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
74. Nutt J.G., Obeso J.A., and Stocchi F. Continuous dopamine receptor stimulation in advanced Parkinson's disease. Trends Neurosci 23 (2000) 109-115
75. Stocchi F., Ruggieri S., Vacca L., and Olanow C.W. Prospective randomized trial of lisuride infusion versus oral levodopa in PD patients. Brain 125 (2002) 2058-2066
76. Kurlan R., Rubin A.J., Miller C., Rivera-Calimlim L., Clarke A., and Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: Preliminary observations. Ann Neurol 20 (1986) 262-265
77. Syed N., Murphy J., Zimmerman T., Mark M.H., and Sage J.I. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 13 (1998) 336-338
78. Stocchi F., Vacca L., Ruggieri S., and Olanow C.W. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62 (2005) 905-910
79. Pahwa R., Busenbark K., Huber S.J., Michalek D., Hubble J.P., and Koller W.C. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 43 (1993) 677-681
80. Koller W.C., Hutton J.T., Tolosa E., and Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53 (1999) 1012-1019
81. Yeh K.C., August T.F., and Bush D.F. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 39 Suppl 2 (1989) 25-38
82. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., Carter J.H., et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 (1994) 913-919
83. The Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42 (1997) 747-755
84. Deane K.H., Spieker S., and Clarke C.E. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 4 (2004) CD004554.
85. Olanow C.W., and Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?. Neurology 62 Suppl 1 (2004) S72-S81
86. Golbe L.I., Lieberman A.N., Muenter M.D., Ahlskog J.E., Gopinathan G., Neophytides A.N., et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 11 (1988) 45-55
87. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 62 (2005) 241-248
88. Rascol O., Brooks D.J., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 (2005) 947-954
89. Clarke A., Brewer F., Johnson E.S., Mallard N., Hartig F., Taylor S., et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110 (2003) 1241-1255
90. Waters C.H., Sethi K.D., Hauser R.A., Molho E., Bertoni J.M., and the Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19 (2004) 426-432